QuarterHawk — Equity ResearchQuarterHawk — Equity Research

Dr. Reddy's Laboratories Limited (RDY)

Healthcare

No action
Fundamental
3
Sentiment
2
Technical
4

Do Nothing: qualitativeScore is 2 (below the required floor of 3) — the upstream qualitative screen's conflicting-catalyst cap (bearish Q2 FY2027 print, fresh USFDA Form 483, sell-side targets clustered at or below spot) hard-blocks any new long regardless of chart quality; the chart itself is trend-aligned (price above SMA20/50/200, MACD positive and expanding, ADX 28.7 rising) but overbought into the 14.33 rejection, so no production entry is emitted.

Analysis as of 2026-10-30· more than 2 trading days ago

Company overview

Dr. Reddy's Laboratories Limited operates as a global pharmaceutical company with divisions in generics, proprietary products, and active pharmaceutical ingredients. It manufactures and sells both branded and generic drugs, provides contract research services, and develops treatments for various therapeutic areas including oncology and inflammatory conditions.

Fundamental

fair
Fundamental3
Mixed fundamentals

Strong liquidity and low leverage are offset by deteriorating earnings and cash flow.

Mixed: profitable and essentially net cash, but earnings and cash flow are deteriorating fast. H1 FY2027 net profit roughly halved and operating cash flow fell about 86% as U.S. lenalidomide pricing collapsed, leaving the ADR at about 40x depressed TTM earnings and above both DCF outputs. Strong liquidity and low leverage offset the damage, but evidence of U.S. revenue stabilization is needed before this deserves more than watchlist status.

Sentiment

weak
Sentiment2
Weak sentiment

Media sentiment is neutral with no retail momentum, and conflicting catalysts create uncertainty.

The dominant driver is the bearish Q2 FY2027 print (2026-10-23, announced) — revenue −1.5% YoY, EBITDA margin −614 bps YoY, net income down and a stock that sold off — compounded by a fresh USFDA Form 483 with three observations at the Visakhapatnam FTO-9 site (2026-10-16, announced), with the only bullish leg being a forward semaglutide supply relaunch guided for November 2026. The 14-day news delta is flat (baseline polarity_score ≈ +0.04 → scoring ≈ −0.03), retail is indeterminate (no Reddit coverage at all), a moderate red-flag cap applied for conflicting catalyst signals, and because the realized bearish items outweigh a single forward bullish expectation the settled read is weak and bearish-tilted rather than a balanced mixed setup.

Technical

good
Technical4
Trend-aligned but overbought

Price is in an uptrend above key averages, but overbought conditions suggest caution.

Trend-aligned bullish structure: price 14.17 sits above SMA20 13.10, SMA50 12.54, SMA200 13.21, EMA9 13.71, EMA21 13.24, WMA9 13.84, WMA21 13.39 and DEMA14 14.00, with MACD 0.44/0.33 (histogram 0.12, expanding) and ADX 28.73 rising from 16.66 ten sessions ago, volume confirming on up-days. The one weak signal is short-term extension: RSI14 77.68 and Williams %R -9.52 are overbought and the tape was rejected at 14.33 on 2026-10-29. Hence technicalScore 4 rather than 5. No production entry: qualitativeScore 2 is below the required floor of 3, a hard block independent of chart quality — Do Nothing.

You’re looking at 2026-10-30 — more than 2 trading days ago.

Subscribers saw this then, and see today’s score, verdict and trade plan now.

Not financial advice. For informational and educational purposes only.